Loading
A pill that blocks tumour blood vessels plus immunotherapy extended survival after chemotherapy, including in tumours that immunotherapy alone does not touch.
OS 18.3 vs 11.4 months in all comers (HR 0.62) and 17.4 vs 12.0 months in pMMR (HR 0.68); PFS 7.2 vs 3.8 months (NEJM 2022). Full approval 2021 for pMMR disease after platinum. Toxicity is substantial: hypertension, hypothyroidism, diarrhoea, and dose reductions in two-thirds of patients. Now largely used after first-line chemo-immunotherapy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
827 enrolled.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eisai, Lenvatinib, Anti-angiogenic therapy, Pembrolizumab.
Shares KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Eisai, Lenvatinib, Anti-angiogenic therapy, Pembrolizumab.
Shares Advanced or recurrent endometrial cancer, Lenvatinib, Anti-angiogenic therapy, Endometrial cancer.
Shares Eisai, Lenvatinib, Anti-angiogenic therapy, Pembrolizumab.
Shares Endometrial cancer with no specific molecular profile, Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Lenvatinib + pembrolizumab (pMMR endometrial cancer after platinum), Anti-angiogenic therapy, Endometrial cancer, Pembrolizumab.
Shares Eisai, Lenvatinib, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/